Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 6/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.52 |
| ▸ | PLK1 | P53350 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393415 | 0.83 | TP53 (0.36) | CES2CES1CA1CA2MAPT | |
| SCHEMBL1031217 | 0.83 | CES2 (0.53) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL6997144 | 0.81 | ELANE (0.53) | MAPTMEN1LMNARAB9AKMT2A | |
| SCHEMBL3890043 | 0.80 | CES2 (0.50) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL4248781 | 0.80 | PARP10 (0.56) | PARP10PLK1MAPTLMNARAB9A | |
| SCHEMBL8717053 | 0.79 | CES2 (0.64) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL6997537 | 0.79 | CES2 (0.61) | CES2CES1PARP1MAPTMEN1 | |
| SCHEMBL811028 | 0.78 | ALDH1A1 (0.50) | CES2CES1MAPTGSK3BMEN1 | |
| SCHEMBL2922979 | 0.78 | CES2 (0.61) | CES2CES1CA1CA2PARP10 | |
| SCHEMBL9278503 | 0.78 | CES2 (0.61) | CES2CES1CA1CA2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197113-B | Combretastatin A-4 derivative containing thiourea structure, preparation method and application thereof | 南通大学 | 2023-08-18 | — | — | CN | disclosed |
| CN-115197113-A | Combretastatin A-4 derivative containing thiourea structure, preparation method and application thereof | 南通大学 | 2022-10-18 | — | — | CN | disclosed |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-12-02 | — | — | US | disclosed |
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-11-19 | — | — | US | disclosed |
| US-10556860-B2 | hTERT modulators and methods of use | ARIZONA BOARD OF REGENTS (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2018-12-06 | — | — | US | disclosed |
| EP-3383841-A1 | hTERT MODULATORS AND METHODS OF USE | The Arizona Board of Regents On Behalf of the University of Arizona (US) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017095969-A1 | hTERT MODULATORS AND METHODS OF USE | THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-06-08 | — | — | WO | disclosed |
| EP-2838531-B1 | INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ANNJI PHARM CO LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8946282-B2 | Indolin-2-one derivatives as protein kinase inhibitors | Annji Pharmaceutical Co., Ltd. (TW) | 2015-02-03 | — | — | US | disclosed |
| EP-1565447-A1 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CJ Corporation (KR) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004048347-A1 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | CJ CORPORATION (KR) | 2004-06-10 | — | — | WO | disclosed |
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | disclosed |
| EP-0874809-B1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-27 | — | — | EP | disclosed |
| US-6239175-B1 | Carbamoyloxy derivatives of mutiline and their use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-29 | — | — | US | disclosed |
| US-6020368-A | MICROBIOCIDES | HINKS JEREMY DAVID (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0874809-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997025309-A1 | CARBAMOYLOXY DERIVATIVES OF MUTILINE AND THEIR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 1997-07-17 | — | — | WO | disclosed |
| US-5386057-A | Process for the preparation of acyl isocyanates | SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) | 1995-01-31 | — | — | US | disclosed |
| EP-0000656-B1 | 4\"-UREIDO-OLEANDOMYCIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | PFIZER INC. (US) | 1981-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361860-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | CES2 4208/4885CES1 2844/4885CA1 4389/4885 |
| US-10556860-B2 | hTERT modulators and methods of use | TERT, POT1, TERF2 | CES2 4566/4885CES1 3674/4885CA1 4124/4885 |
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | ESR2, ESRRA, ESRRG | CES2 1441/4885CES1 780/4885CA1 3338/4885 |
| US-20210371375-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, TERF2, RB1 | CES2 4014/4885CES1 3386/4885CA1 4573/4885 |
| US-20180346415-A1 | hTERT MODULATORS AND METHODS OF USE | TERT, POT1, TERF2 | CES2 4566/4885CES1 3674/4885CA1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.